Latest Healthcare News

Page 1 of 186
EBOS Group Limited has updated its interim dividend announcement, specifying the Dividend Reinvestment Plan strike price and confirming payment details for the six-month period ending December 2025.
Ada Torres
Ada Torres
18 Mar 2026
Biotron Limited reveals that its lead antiviral candidate BIT-HBV001 shows promising activity against Hepatitis Delta Virus, expanding its potential impact beyond Hepatitis B. Meanwhile, the company completes integration of Sedarex and advances regulatory plans for its anaesthetic SedRx.
Ada Torres
Ada Torres
18 Mar 2026
Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.
Ada Torres
Ada Torres
17 Mar 2026
Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.
Ada Torres
Ada Torres
17 Mar 2026
Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.
Ada Torres
Ada Torres
17 Mar 2026
Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.
Ada Torres
Ada Torres
17 Mar 2026
Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.
Ada Torres
Ada Torres
17 Mar 2026
Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.
Ada Torres
Ada Torres
16 Mar 2026
BlinkLab has completed onboarding its tenth and final clinical site for its pivotal FDA 510(k) trial of an AI-powered autism diagnostic aid, setting the stage for patient enrolment to begin this month.
Ada Torres
Ada Torres
16 Mar 2026
Cann Group Limited has raised $750,000 through a convertible note agreement with Obsidian Global, aiming to strengthen its working capital and move towards EBITDA positivity.
Ada Torres
Ada Torres
16 Mar 2026
Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.
Ada Torres
Ada Torres
16 Mar 2026
Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.
Ada Torres
Ada Torres
16 Mar 2026